Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib in RAIR Differentiated Thyroid Cancer
NCT03573960Phase 4Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2018
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenvatinib in differentiated thyroid cancer (DTC), sponsored by Eisai Co., Ltd. Primary endpoints: Percentage of Participants with Grade 2 or Higher Treatment-emergent Adverse Events at 24 weeks, Number of Dose Reductions at 24 weeks and 1 more. Started Apr 2018; status: completed.
02
Drugs
lenvatinib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT03573960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573960.